fenfluramine (Pondimin, Ponderil, Ponderex, Adipomin, Fintepla)
Jump to navigation
Jump to search
Introduction
Tradename: Pondimin. DEA-controlled substance: class 2. DEA-controlled substance: class 4[3].
Withdrawn from US market in 1997 following case reports of heart valve abnormalities in patients using flenfluramine or dexfenfluramine for appetite suppression[3].
Indications
- obesity
- Dravet syndrome in patients age >= 2 years of age (Fintepla)[6]
Dosage
- start 20 mg PO BID
- max: 120 mg/day
- Dravet syndrome: low-dose (Fintepla)[6]
Tabs: 20 mg.
Pharmacokinetics
- metabolized in liver to largely inactive metabolites
- metabolites excreted by the kidney
- 1/2life: 11-30 hours
elimination via kidney
1/2life = 11-30 hours
Adverse effects
- insomnia
- agitation
- nervousness
- hyperthermia
- hyperventilation
- hypertension
- convulsions
- pulmonary hypertension
- valvular heart disease
- mild aortic regurgitation (6 months of therapy)
- no significant cardiac risk after 3 months of therapy[5] Test interferences:
- may cause false positives in immunoassays for amphetamines in urine
- drug adverse effects of analeptics
- drug adverse effects of psychotropic agents
- drug adverse effects of sympathomimetic(s)
Mechanism of action
More general terms
- adrenergic neuron stimulant
- analeptic (CNS stimulant)
- anorexiant (appetite suppressant)
- amine
- aromatic compound
More specific terms
Component of
References
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- ↑ Clinical Guide to Laboratory Tests, 3rd ed. Teitz ed., W.B. Saunders, 1995
- ↑ 3.0 3.1 3.2 Fresno Bee, Dec. 2000
- ↑ Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 461
- ↑ 5.0 5.1 Journal Watch 21(13):109, 2001 Davidoff et al, Arch Intern Med 161:1429, 2001
- ↑ 6.0 6.1 6.2 George J New Drug Approved for Rare Childhood Seizures - Fenfluramine reduced convulsive seizures in Dravet syndrome MedPage Today June 26, 2020 https://www.medpagetoday.com/washington-watch/fdageneral/87282